黄世腾, 杨瑞军, 吕磊, 陈旭富, 叶承华, 万圣, 游佳玲. 2021-2022年浙江省衢州市B/Victoria系流行性感冒病毒抗原性及基因特性分析[J]. 疾病监测, 2023, 38(7): 859-864. DOI: 10.3784/jbjc.202212280553
引用本文: 黄世腾, 杨瑞军, 吕磊, 陈旭富, 叶承华, 万圣, 游佳玲. 2021-2022年浙江省衢州市B/Victoria系流行性感冒病毒抗原性及基因特性分析[J]. 疾病监测, 2023, 38(7): 859-864. DOI: 10.3784/jbjc.202212280553
Huang Shiteng, Yang Ruijun, Lyu Lei, Chen Xufu, Ye Chenghua, Wan Sheng, You Jialing. Antigenic and genetic characteristics of influenza B virus Victoria lineage in Quzhou, Zhejiang, 2021−2022[J]. Disease Surveillance, 2023, 38(7): 859-864. DOI: 10.3784/jbjc.202212280553
Citation: Huang Shiteng, Yang Ruijun, Lyu Lei, Chen Xufu, Ye Chenghua, Wan Sheng, You Jialing. Antigenic and genetic characteristics of influenza B virus Victoria lineage in Quzhou, Zhejiang, 2021−2022[J]. Disease Surveillance, 2023, 38(7): 859-864. DOI: 10.3784/jbjc.202212280553

2021-2022年浙江省衢州市B/Victoria系流行性感冒病毒抗原性及基因特性分析

Antigenic and genetic characteristics of influenza B virus Victoria lineage in Quzhou, Zhejiang, 2021−2022

  • 摘要:
      目的  了解浙江省衢州市2021—2022年B/Victoria系流行性感冒(流感)病毒抗原性及基因进化特征,为流感防控提供科学依据。
      方法  选取衢州市2021—2022年分离到的14株B/Victoria系流感毒株进行全基因组测序,利用生物信息学软件对其血凝素(HA)和神经氨酸酶(NA)基因进行分子进化特征分析。 采用红细胞凝集抑制实验进行抗原性分析。
      结果  10株分离株为同期疫苗株B/Washington/02/2019的类似株,后期分离的4株毒株为疫苗株B/Washington/02/2019的低反应株。 同源性分析显示,分离株与下一年度(2022—2023年)疫苗株B/Austria/1359417/2021的匹配性总体高于同期疫苗株B/Washington/02/2019。 基因进化分析发现,14株分离株从V1A.3a.1逐渐进化为V1A.3a.2分支,与同期疫苗株B/Washington/02/2019的遗传距离随时间逐渐加大,而与下一年度疫苗株B/Austria/1359417/2021关系渐近且最终聚集在V1A.3a.2分支上。 相较于同期疫苗株B/Washington/02/2019,HA氨基酸序列共有14个变异位点,涉及3个抗原表位和1个糖基化位点(197NET);NA蛋白发生了多个氨基酸位点改变,但未发现相关耐药位点变异。
      结论  2021—2022年衢州市B/Victoria系流感病毒处在持续进化之中,与同期疫苗株B/Washington/02/2019的匹配性降低,应继续加强对B/Victoria系流感病毒的监测研究,及时为流感疫苗株的筛选提供科学依据。

     

    Abstract:
      Objective  To understand the antigenicity and genetic characteristics of influenza B virus Victoria lineage isolated in Quzhou, Zhejiang, from 2021 to 2022, and to provide evidence for the prevention and control of influenza.
      Methods  A total of 14 influenza B virus Victoria lineage strains isolated in Quzhou during 2021−2022 were selected for whole genome sequencing and bioinformatics software was used to analyze the evolutionary variation characteristics. The antigenicity of the strains was analyzed by hemagglutination inhibition test.
      Results  In the 14 strains of influenza B virus Victoria lineage, 10 were similar strains of the contemporaneous vaccine strain B/Washington/02/2019, and 4 were less reactive strains. The phylogenetic analysis showed that the isolated strains of influenza B virus Victoria lineage evolved into clades of V1A.3a.2 from V1A.3a.1. The strains were far from B/Washington/02/201, but close to B/Austria/1359417/2021 in the following year (2022−2023), and clustered in clade V1A.3a.2. The hemagglutinin (HA) amino acid sites of the isolated strains changed compared with the vaccine strain B/Washington/02/2019, involving 14 amino acid mutations. These variations covered 3 antigenic epitopes and 1 glycosylation site (197NET). There were multiple mutation sites of the amino acids of neuraminidase (NA), but no mutation were found in the drug resistant sites of NA.
      Conclusion  The results revealed the obvious evolution trend of influenza B virus Victoria lineage isolated in Quzhou during 2021−2022, and the matching degree between the B/Victoria strains isolated and contemporaneous vaccine strain B/Washington/02/2019 was reduced. Therefore, surveillance for influenza B virus Victoria lineage should be strengthened to provide evidence for the recommendation of influenza B virus vaccine strains.

     

/

返回文章
返回